<DOC>
	<DOC>NCT02231424</DOC>
	<brief_summary>The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual速 metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Berodual速 Metered-dose Inhaler in Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Fenoterol, ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Patients of either sex, including children over 6 years Chronic obstructive respiratory tract disease. Every doctor was asked to include in this study the first patients coming after each other, who were treated for the first time with Berodual速 metered dose inhaler (MDI) Contraindications listed in the Instructions for Use/Summary of Product Characteristics of Berodual速 metereddose inhaler</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>